Th-LAK细胞对肺癌试验治疗的观察

OBSERVATION ON CLINICAL TRIAL TREATMENT FOR LUNG CANCER WITH Th-LAK

利用Th-LAK细胞对46例肺癌患者进行了临床试验治疗的观察。结果表明,71.7%的病例原有症状和体征都有不同程度的改善;各期综合的一年生存率为82.6%,高于其它疗法的生存率;部分病例的肿瘤及转移淋巴结有不同程度的缩小。

The thymal lymphocytes of the fetus above 6 monthes were used as theprecursor to make Th-LAK cells, Forty-six cases of lung cancer patients were treated with Th-LAK cells by the ways of subcutaneous, intramuscular, orlocal injection.The duration of the therapy ranged from 15～180 days (most around30～60 days). The results were as follows. Symptoms and signs were improved invarying degrees in 71.7% of the cases,espicially on alleviating pain and subsidinghydrothorax. Fatient's survival time was prolonged.The one year survival rate was82.6%, higher than that of other therapy. The tumor size or metastatic lymphnode were reduced in some cases in varying degrees. All above suggests thatTh-LAK cell has certain therapeutic effects on lung cancer.